Complement inhibitors under advanced clinical development in hematologic diseases
| Agent . | Target . | Disease . | Phase of development . |
|---|---|---|---|
| Crovalimab | C5 | PNH | 3 |
| Danicopan | Factor D | PNH | 3 |
| ACH-5528/ALXN-2050 | Factor D | PNH | 2 |
| BCX9930 | Factor D | PNH | 2 |
| Iptacopan | Factor B | PNH | 3 |
| Sutimlimab | C1s | CAD | 3 |
| Pegcetacoplan | C3 | AIHA PNH | 2 Early-access program |
| Narsoplimab | MASP-2 | TA-TMA | Expanded-access program |
| Ravulizumab | C5 | TA-TMA | 3 |
| Coversin | C5 and LTB4 inhibition | TA-TMA | 3 |
| Agent . | Target . | Disease . | Phase of development . |
|---|---|---|---|
| Crovalimab | C5 | PNH | 3 |
| Danicopan | Factor D | PNH | 3 |
| ACH-5528/ALXN-2050 | Factor D | PNH | 2 |
| BCX9930 | Factor D | PNH | 2 |
| Iptacopan | Factor B | PNH | 3 |
| Sutimlimab | C1s | CAD | 3 |
| Pegcetacoplan | C3 | AIHA PNH | 2 Early-access program |
| Narsoplimab | MASP-2 | TA-TMA | Expanded-access program |
| Ravulizumab | C5 | TA-TMA | 3 |
| Coversin | C5 and LTB4 inhibition | TA-TMA | 3 |
AIHA, autoimmune hemolytic anemia; LTB4, leukotriene B4.